logo
logo

FutureTech II to merge with Longevity Biomedical

Apr 09, 20254 months ago

Acquiring Company

FutureTech II Acquisition

Acquired Company

Longevity Biomedical

DelawareBiotechnologyHealth Care

Description

FutureTech II Acquisition Corp. has entered into a merger agreement with Longevity Biomedical Inc. The merger will transform Longevity into a wholly-owned subsidiary. The combined company is expected to list on Nasdaq under the symbol 'LBIO'. This move aligns with FutureTech's strategy of targeting innovative companies in the technology sector.

Company Information

Company

FutureTech II Acquisition

Location

Delaware, United States

About

FutureTech II Acquisition Corp. is a blank check company focused on the disruptive technology sector in the U.S. The company was incorporated in Delaware in 2021 with the purpose of effecting a merger or similar business combination. It completed its Initial Public Offering in 2022, raising $115 million. FutureTech targets private companies with positive cash flow or compelling technology.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed